What is the 13F Pro Quality Score for PBYI?

13F Pro ranks PUMA BIOTECHNOLOGY, INC. (PBYI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PBYI's current score at https://13fpro.ai/company/PBYI (free sign-up required for the full ranking).

Which hedge funds own the most PBYI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PBYI include ACORN CAPITAL ADVISORS,, BlackRock,, AMERICAN CENTURY COMPANIES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PBYI as soon as new 13F filings post.

Where does 13F Pro source PBYI data?

All PUMA BIOTECHNOLOGY, INC. fundamentals and ownership data come directly from SEC EDGAR. PUMA BIOTECHNOLOGY, INC. files with the SEC under CIK 1401667. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PBYI in?

PUMA BIOTECHNOLOGY, INC. (PBYI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PBYI research updated on 13F Pro?

PBYI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PUMA BIOTECHNOLOGY, INC.(PBYI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1401667 PBYI stock profile & AI dashboard →

13F Pro Quality Score

53.8/100

Rank #1,369 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

50.4/100

Profitability

54.0/100

Balance Sheet

91.5/100

Earnings Quality

75.2/100

Free Cash Flow

69.9/100

Institutional Flow

34.4/100

Revenue Scale

25.7/100

Dilution Risk

32.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PBYI Scores 54/100

exact factor attribution · 2026-09-11

PBYI's composite is driven by capital efficiency and free cash flow, held back by scale and earnings growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Capital efficiency

+4.2 pts

92th pct

Free cash flow

+3.0 pts

70th pct

Earnings quality

+2.5 pts

75th pct

Profitability

+0.6 pts

54th pct

Revenue growth

+0.1 pts

50th pct

Institutional flow

-0.8 pts

34th pct

Shareholder dilution

-0.9 pts

32th pct

Earnings growth

-1.2 pts

25th pct

Scale

-3.6 pts

26th pct

Latest change (2026-08-06): 53 → 59 · ↑ Profit margin 60→79; ↑ Earnings growth 30→96; despite ↓ Free cash flow 80→49

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PBYI Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for PUMA BIOTECHNOLOGY, INC. (PBYI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PBYI at 53.8/100 on a 32-signal composite quality model, placing it at rank #1,369 of 2,962 stocks — the top half of the AI-ranked universe. PBYI scores in the top quartile across balance sheet strength (91.5), earnings quality (75.2). Areas of concern include revenue scale (25.7) and institutional flow (34.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 32.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PUMA BIOTECHNOLOGY, INC. reports quarterly revenue of $56.5M, net income of $8.2M, an operating margin of 13.4%. Top institutional holders of PBYI by reported 13-F value include ACORN CAPITAL ADVISORS, BlackRock, AMERICAN CENTURY COMPANIES, based on the most recent SEC filings. PBYI trades on the Nasdaq exchange and files with the SEC under CIK 1401667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBYI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PUMA BIOTECHNOLOGY, INC. directly from SEC EDGAR. PUMA BIOTECHNOLOGY, INC.'s 13F Pro composite quality score has ranged between 19 and 68 since 2021, currently 53.8 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about PUMA BIOTECHNOLOGY, INC.

Quirks, history, and lore behind PBYI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Los Angeles, California · focused on oncology.
2
The Numbers
A small-cap biopharma with limited commercial revenue and a history of operating losses — the classic profile of a company betting everything on one approved drug.
3
The History
Founded in the early 2010s, the company spent years developing a therapy targeting a specific breast cancer mutation pathway before winning FDA approval.
4
The Secret
Its entire pipeline centers on irreversible HER2 inhibition — blocking a protein that drives some of the most aggressive forms of breast and gastric cancers.
5
The Lore
Its flagship drug, neratinib, targets HER2-positive patients who've already been through standard therapy — giving hope to women who thought they'd run out of options.
6
The Giveaway
The name sounds like a big cat sportswear brand, but this company is all about neratinib and fighting HER2-driven cancers — no sneakers involved.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$56.5M

Net Income

Q2 2026

$8.2M

Free Cash Flow

Q2 2026

$1.6M

Operating Margin

Q2 2026

13.4%

ROIC

Q2 2026

21.9%

D/E Ratio

Q2 2026

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-0.9% YoY

$228.4MFY 2025

FY22 $228.0MFY23 $235.6MFY24 $230.5MFY25 $228.4M

Net Income

+2.8% YoY

$31.1MFY 2025

FY22 $2.0KFY23 $21.6MFY24 $30.3MFY25 $31.1M

Operating Income

+20.5% YoY

$37.3MFY 2025

FY22 $23.7MFY23 $32.6MFY24 $31.0MFY25 $37.3M

EPS (Diluted)

-1.6% YoY

$0.61FY 2025

FY22 $0.00FY23 $0.45FY24 $0.62FY25 $0.61

Total Assets

+1.4% YoY

$216.3MFY 2025

FY22 $222.1MFY23 $230.5MFY24 $213.3MFY25 $216.3M

Total Debt

-60.1% YoY

$45.2MFY 2025

FY22 $102.0MFY23 $136.0MFY24 $113.3MFY25 $45.2M

Op. Cash Flow

+7.4% YoY

$41.8MFY 2025

FY22 $-15.8MFY23 $27.0MFY24 $38.9MFY25 $41.8M

Free Cash Flow

+7.4% YoY

$41.7MFY 2025

FY22 $-15.8MFY23 $26.9MFY24 $38.9MFY25 $41.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$228.4M -0.9%	$230.5M -2.2%	$235.6M +3.3%	$228.0M -9.9%	$253.2M +12.5%	$225.1M
Net Income	$31.1M +2.8%	$30.3M +40.2%	$21.6M +1079450.0%	$2.0K +100.0%	$-29.1M +51.5%	$-60.0M
Operating Income	$37.3M +20.5%	$31.0M -5.1%	$32.6M +37.6%	$23.7M +1738.8%	$1.3M +104.2%	$-30.4M
EPS (Diluted)	$0.61 -1.6%	$0.62 +37.8%	$0.45	$0.00 +100.0%	$-0.72 +52.6%	$-1.52
Total Assets	$216.3M +1.4%	$213.3M -7.5%	$230.5M +3.8%	$222.1M -2.0%	$226.6M -7.2%	$244.2M
Total Debt	$45.2M -60.1%	$113.3M -16.7%	$136.0M +33.3%	$102.0M +0.0%	$102.0M +3.8%	$98.3M
Operating Cash Flow	$41.8M +7.4%	$38.9M +44.1%	$27.0M +270.7%	$-15.8M -176.6%	$20.6M +2571.4%	$773.0K
Free Cash Flow	$41.7M +7.4%	$38.9M +44.6%	$26.9M +269.8%	$-15.8M -176.6%	$20.6M +2740.4%	$727.0K

Get alerted when PBYI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PUMA BIOTECHNOLOGY, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PBYI

ACORN CAPITAL ADVISORS, LLC
$33.5M4,131,299 sh
BlackRock, Inc.
$30.9M3,804,736 sh
AMERICAN CENTURY COMPANIES INC
$18.8M2,319,996 sh
ACADIAN ASSET MANAGEMENT LLC
$16.6M2,053,523 sh
RENAISSANCE TECHNOLOGIES LLC
$14.9M1,836,213 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.9M1,835,643 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$14.8M1,825,599 sh
LSV ASSET MANAGEMENT
$13.1M1,617,981 sh
DIMENSIONAL FUND ADVISORS LP
$12.3M1,518,014 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.9M1,339,405 sh

Fund	Value	Shares
ACORN CAPITAL ADVISORS, LLC	$33.5M	4,131,299
BlackRock, Inc.	$30.9M	3,804,736
AMERICAN CENTURY COMPANIES INC	$18.8M	2,319,996
ACADIAN ASSET MANAGEMENT LLC	$16.6M	2,053,523
RENAISSANCE TECHNOLOGIES LLC	$14.9M	1,836,213
VANGUARD CAPITAL MANAGEMENT LLC	$14.9M	1,835,643
VANGUARD PORTFOLIO MANAGEMENT LLC	$14.8M	1,825,599
LSV ASSET MANAGEMENT	$13.1M	1,617,981
DIMENSIONAL FUND ADVISORS LP	$12.3M	1,518,014
GEODE CAPITAL MANAGEMENT, LLC	$10.9M	1,339,405

Companies Similar to PBYI

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INMD

InMode Ltd.

AI score

Similar quality profile · 7 shared holders

LSV ASSET MANAGEMENT Kathmere Capital Management, LLC Baron Wealth Management LLC

AMPH

Amphastar Pharmaceuticals, Inc.

AI score

Similar quality profile · 5 shared holders

LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC China Universal Asset Management Co., Ltd.

BVS

Bioventus Inc.

AI score

Similar quality profile · 6 shared holders

KENNEDY CAPITAL MANAGEMENT LLC GLOBEFLEX CAPITAL L P LSV ASSET MANAGEMENT

NRC

NRC HEALTH

AI score

Similar quality profile · 3 shared holders

R Squared Ltd DGS Capital Management, LLC WealthCollab, LLC

EMBC

Embecta Corp.

AI score

Similar quality profile · 5 shared holders

LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC One Wealth Advisors, LLC

Pediatrix Medical Group, Inc.

AI score

Similar quality profile · 7 shared holders

LSV ASSET MANAGEMENT Round Rock Advisors, LLC GLOBEFLEX CAPITAL L P

COLL

COLLEGIUM PHARMACEUTICAL, INC

AI score

Similar quality profile · 10 shared holders

LSV ASSET MANAGEMENT GLOBEFLEX CAPITAL L P Round Rock Advisors, LLC

HAE

HAEMONETICS CORP

AI score

Similar quality profile · 2 shared holders

MARTINGALE ASSET MANAGEMENT L P Abel Hall, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PBYI on your watchlist

Track score changes the day PUMA BIOTECHNOLOGY, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PBYI a good stock to buy?

13F Pro's AI-powered analysis of PUMA BIOTECHNOLOGY, INC. (PBYI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PBYI are available on the PBYI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PBYI is classified as a small company.

Which hedge funds own PBYI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PBYI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PUMA BIOTECHNOLOGY, INC.'s investment landscape.